HomeB1NT34 • BVMF
add
Biontech Se Bdr
Previous close
R$32.80
Day range
R$33.12 - R$33.65
Year range
R$26.80 - R$49.05
Market cap
22.26B USD
Avg Volume
669.00
Market news
FXLeaders
21 hours ago
Dow Jones (DJIA), Nasdaq Weekly Forecast – Bullish Break or Bear Reversal Next?
0.29%
0.27%
Financials
Income Statement
Revenue
Net income
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 182.80M | -2.56% |
Operating expense | 593.40M | -6.05% |
Net income | -415.80M | -31.96% |
Net profit margin | -227.46 | -35.43% |
Earnings per share | -1.73 | -32.06% |
EBITDA | -451.60M | 2.84% |
Effective tax rate | 6.65% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.11B | -9.94% |
Total assets | 21.18B | -4.83% |
Total liabilities | 2.26B | -1.43% |
Total equity | 18.93B | — |
Shares outstanding | 240.39M | — |
Price to book | 0.42 | — |
Return on assets | -5.65% | — |
Return on capital | -6.36% | — |
Cash Flow
Net change in cash
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -415.80M | -31.96% |
Cash from operations | -780.70M | -146.04% |
Cash from investing | 1.25B | 154.11% |
Cash from financing | -13.80M | -76.92% |
Net change in cash | 423.00M | 115.74% |
Free cash flow | -1.37B | -175.36% |
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
6,772
